Search Results

Pendopharm is pleased to announce the renewal of its exclusive distribution agreement with Anika Therapeutics Inc (NASDAQ: ANIK) (Anika) for Cingal ® , Monovisc ® and Orthovisc ® through the end of 2030.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that on June 3, 2024, Anika granted: non-statutory stock options covering 96,525 shares of common stock at a per share exercise price of $29.35.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, reported financial results for its first quarter ended March 31, 2024.

Anika Therapeutics, Inc., a global joint preservation company in early intervention orthopedics, announced that it has appointed Steve Griffin as the Company’s Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024.

Anika Therapeutics, Inc. today announced that management will participate in the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024.

Anika Therapeutics, Inc. announced that on May 1, 2024, Anika granted non-statutory stock options covering an aggregate of 3,800 shares of common stock at a per share exercise price of $26.49, which equaled the closing price of common stock on the Nasdaq Global Select Market on the grant date, to one newly hired non-executive employee.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its fourth quarter and full year ended December 31, 2023.